-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 IMbB1RV7kSBe+lP+Flym3fd9X9NYr5t1xeiAapKLznL9bLzXuoqWbHwBv3xHOCOb
 Xy3njztpoku52LQGPqQVmw==

<SEC-DOCUMENT>0001144204-08-032438.txt : 20080528
<SEC-HEADER>0001144204-08-032438.hdr.sgml : 20080528
<ACCEPTANCE-DATETIME>20080528163126
ACCESSION NUMBER:		0001144204-08-032438
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20080528
FILED AS OF DATE:		20080528
DATE AS OF CHANGE:		20080528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		08863857

	BUSINESS ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
		BUSINESS PHONE:		972-8-930-4440

	MAIL ADDRESS:	
		STREET 1:		711 EXECUTIVE BOULEVARD
		STREET 2:		SUITE Q
		CITY:			VALLEY COTTAGE
		STATE:			NY
		ZIP:			10989
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v115939_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16 </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      May
      28, 2008</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Ltd. </strong></font>
      <div>
        <hr style="COLOR: black" align="center" noshade size="1" width="40%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>711
      Executive Blvd., Suite Q</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Valley
      Cottage, New York 10989 </strong></font>
      <div>
        <hr style="COLOR: black" align="center" noshade size="1" width="30%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): <font style="FONT-FAMILY: Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font style="FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No
<font style="FONT-FAMILY: Wingdings">x</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
      N/A
</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="logo.jpg" alt="xtl"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><br></font>
      <div align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Incorporation
        by Reference: This Form 6-K of XTL Biopharmaceuticals Ltd. dated May 28,
        2008 is
        hereby incorporated by reference into the registration statements on Form
        F-3
        (File No. 333-141529 and File No. 333-147024) filed by XTL Biopharmaceuticals
        Ltd. with the Securities and Exchange Commission on March 23, 2007 and October
        30, 2007, respectively and the registration statements on Form S-8 (File
        No.
        333-148058 and File No. 333-148574) filed by XTL Biopharmaceuticals Ltd.
        with
        the Securities and Exchange Commission on December 14, 2007 and January 18,
        2008, respectively.</strong></font></div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      Biopharmaceuticals Announces Appointment of Laurence N. Charney to Board of
      Directors</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 36pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>VALLEY
      COTTAGE, NEW YORK, May 28, 2008 &#8211;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; TASE: XTL) today announced that Laurence
      N. Charney, CPA, has been appointed to XTL's Board of Directors. The
      appointment, effective immediately, increases the size of XTL&#8217;s Board to six
      members.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mr.
      Charney, 61, recently retired from his position as a Partner of Ernst &amp;
Young LLP, an international </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">assurance</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">tax</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">transaction</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">advisory</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      services
      firm, having served that firm for over thirty-five years. At Ernst &amp; Young,
      Mr. Charney most recently served as the Americas Area Director of Conflict
      Management. In that role he had oversight and responsibility in ensuring
      compliance with global and local conflict of interest policies for client and
      engagement acceptance across all service lines. Mr. Charney previously served
      as
      an audit partner where his global practice focused on the media and
      entertainment, telecom and software industries servicing public and private
      companies in addressing their transactional, regulatory, corporate governance,
      Sarbanes-Oxley, tax and accounting challenges. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Since
      July 2007, he has served on the Audit Committee and Board of Directors of Marvel
      Entertainment, Inc. (NYSE: MVL). In June 2007, he completed a term as the
      Chairman of the Audit Committee of UJA - Federation of New York. Mr. Charney
      graduated with a BBA degree from Hofstra University and completed the Executive
      MBA in Business program at Columbia University.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer of XTL, commented &#8220;We are excited to have Larry
      join our Board of Directors. Through his many years of experience in public
      accounting, Larry is well-versed in matters related to SEC and Sarbanes-Oxley
      compliance. We believe that his skills provide a valuable addition to XTL's
      Board, as we prepare for the next stage of the company&#8217;s growth following what
      we hope will be a successful completion of our Phase 2b study of Bicifadine
      in
      Q4 2008.&#8221; </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the development of therapeutics
      for the treatment of diabetic neuropathic pain and HCV. XTL is developing
      Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
      of diabetic neuropathic pain, which is currently in a Phase 2b study. XTL has
      out-licensed its novel pre-clinical HCV small molecule inhibitor program. XTL
      also has an active in-licensing and acquisition program designed to identify
      and
      acquire additional drug candidates. XTL is publicly traded on the NASDAQ and
      Tel-Aviv Stock Exchanges (NASDAQ: XTLB; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Contact:</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ron
      Bentsur, Chief Executive Officer</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
      +1-(845)-267-0707 ext. 225</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Cautionary
      Statement</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Some
      of the statements included in this press release, particularly those
      anticipating future clinical and business prospects for our clinical compound
      for neuropathic pain, Bicifadine, growth and operating strategies and similar
      matters, may be forward-looking statements that involve a number of risks and
      uncertainties. For those statements, we claim the protection of the safe harbor
      for forward-looking statements contained in the Private Securities Litigation
      Reform Act of 1995. Among the factors that could cause our actual results to
      differ materially is our ability to complete in a timely and cost effective
      manner clinical trials on Bicifadine, which could directly impact our ability
      to
      continue to fund our operations; our ability to meet anticipated development
      timelines for all of our drug candidates due to recruitment, clinical trial
      results, manufacturing capabilities or other factors; the success of our drug
      development and marketing arrangements with third parties; and other risk
      factors identified from time to time in our reports filed with the Securities
      and Exchange Commission, including our annual report on Form 20-F filed with
      the
      Securities and Exchange Commission on March 27, 2008. Any forward-looking
      statements set forth in this press release speak only as of the date of this
      press release. We do not intend to update any of these forward-looking
      statements to reflect events or circumstances that occur after the date hereof.
      This press release and prior releases are available at http://www.xtlbio.com.
      The information in our website is not incorporated by reference into this press
      release and is included as an inactive textual reference only.
</em></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" colspan="3" valign="top" width="36%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
                  BIOPHARMACEUTICALS LTD.</strong></font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" colspan="3" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" colspan="3" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                  May 28, 2008</font></div>
              </td>
              <td align="left" valign="top" width="3%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font></div>
              </td>
              <td align="left" valign="top" width="25%" style="border-bottom: black thin solid;">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/
                  <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bill
                  Kessler</font></font></div>
              </td>
              <td align="left" valign="top" width="8%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" colspan="2" valign="top" width="33%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bill
                  Kessler</font></div>
              </td>
            </tr>
            <tr>
              <td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" valign="top" width="3%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td align="left" colspan="2" valign="top" width="33%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
                  <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Director
                    of Finance</font></div>
                </div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,@"E`P$1``(1`0,1`?_$`.$```$#!`,!````````
M``````H("0L``P0'`0(&!0$``0,%`0``````````````"`8'"0`"`P0%`1``
M``4"`P0#"0@($0T!`````0(#!`4&!P`1""$Q$@E!$Q11(A4U%C<X.0IA,F(C
M,S1D-G&!P4)24V9XD;'1@I)#8[-4566U)K;6=QCPH7*BPB1$19476!F:.A$`
M`0(#!0,'!P@'!0<%`````0(#`!$$(3$%!@=!41)A<8$R$S,(D;'!(A0T-O"A
MT4)B(Q4UX5)R0W-T%O&"PI-$LE1%E987-Z*#)"5&_]H`#`,!``(1`Q$`/P`_
M`!RS[T=WX!A#IZ=@8P!+*1-(41'@+QZW"/ESPD?7;JEC]%^DF^NIB1@AJ0;5
MT4[F(FG^T'9IS=0O7#2'IN-<NDRG4;,G$Y)(`X.3-0B`'$H9Y8[66L!7F7'&
M<&4M2&'7!.R4D[;3?=9+?')QW%TX-A3E=UW$),@-\`+T#[2#S.*9O0RN56=Q
MZ3KR@SS*+VH+)*T#2D/1JM-F<D5>PE.2$?'(U/#2#9B4Y&SXS]4XJ9&6*<!$
MN"_J=",HOX-[.SVK5<RUQ%R8]<@72X93WRV;H'5K5;&%UI?4)TZE`!)N29W\
ME]F[EB1=M1<"&NM:VW%SZ<072@;C412==0C=P3@70BJMA&4XR06(0A0!9NV?
ME*<```S`1P%E50BEKJBF65$M.%,Y;093'R,$M0U**ND8>69*<;"NDB<HV#Q&
M+WH$';G]Z80V;]H<6?>]S,<8>,I(0I2B>:-O[U7K33\NF.0`<O>G#[!1_5V8
MR(7P"2N)1WRBI%=JT@GGCG;W#_L1Q?VPW*\ABN!/ZH\L5M[A_P!B.*[8;E>0
MQ7`G]4>6*V]P_P"Q'%=L-RO(8K@3^J/+'7CX3``E-N$V8@(!LW]`]&+2ZHF2
M$$CR18>Q09KDDRWSLWQ>*;BX1`1$HAF`Y9!MVXO_`&K%;H]"TGJBS?%S'D71
MB'$""<2]\<QA#+/:/=``R#=]O&%25(5V\E+`V;N:,)`:5)LI#RS,3,IQW0$#
M")N'A,)2`;>(#EG]]N'+/%-J;6I2T\7'9,&R47I"@27$\+NT[#%\=H"`[A`<
M\95":2.2+C*5MT8RQ@`I?P<]N6>X`VCF`&V@&[NXQ(+A'9MBV5\6K:2\/65)
MM,6R*@?B`"F$`R`5"[0-EEN,`"&60]P-H8L5*E0%/!1<&Y),7-*94GM*=25S
MY1S1D$`"FR`-@E$<Q'OMX;,L;*7`ZV'!.1B]2IF14)[MO/%[%1;%8J*BL5%0
M*Q[2#I_U-T[;NG];VF&]U]:'CK=-&=(7\H2W5S:XIN%-2+EV)*<N:W@H279L
M$W=/R3OL<H9-,!4:KI*&'XDPX>G1;$,M*Q=6`YE9:>+W=NKGZJOU;"`9WW&&
MLU,P[$T40Q##G%I:3UTI/S]/GYX&/T%:^:O=7I>6*ULWCNK=C2?JIIEYI]O8
MRN%<2J:G+1D;6#A).EKH4YY0R$NA!SE!U:5F[,Y2*`B@"H'XR$*`D%GO(*:3
M#/Q?*U.VQF&A5VB5H%I"024RF4D*!(NV\D-5D[,+B:HTF..J<P9\%)0H@R),
MISL,Q?>(>-2]EG@[85G,7.OEK0I1;2%;YN\KBK'4;1+R%N++6\IU):??,968
M<RZU(PO;(9OU3A\V!?B(;B02`Y@##;#7ZLK\-&$X10*&87D)9"S;]Z9`J`G>
M9W<$N2%U3:346'U9Q*I?0K#`OM"B=G!>`#?8;CQ#GAB_6'S0=25]-0]=5O9V
M\MXK)V39GCZ%LG:VW=R*VI*GJ4M)1+-*GZ#8*PT#*QS)27=PS(CETIU?7G<K
MF*81R``=#+VG&7<$P=(S(PU48E4`O/O&?JJ,UJG(R`G/HLAO,PYNQ6HQHT^&
M5+@ID*[-I(X9)'5`%DS9OF>6"7:,T_ZK-*W(<U:7YO7?#4#+ZI+U6RIRN(LD
MY=&X$M4=FZ1\JJ=&DJ9I@[B:</H.IGL3(JOI99KU:XG<@W,.2(A@?<0Q#+68
M=6:3!<*::I\MMK]9P#U5E(/$253ONLER0[=-28SAV0'WWU+<QH3DJ9X@)B5@
MLNF;MM\"0#J^UZ$$P%U*:OA*(B(9W5O&`=S<$R&6W!0HRWILF:D)HE-),I$B
MV6V^=L,;^*YO(':/5*7#LM^C;&`YUJ:WF9Q3>ZL-4K%4`*84'EZ[IM%P*IGP
M'%!S42:H$,`#D.60Y8SMY6R57-\=#04BD`RFF9_Q&-5[,69&%]@Y4U"793M)
M%@OV1>::R]<SXAE66J?5@^1(?JSK,;PW9>HD4X0-U9U&TZJ0JG#MX1'/(<\8
MGLL9`HUAFM8I6UG?8?/%S&/YL>1VK+K[B`>647E]8.N]JFHNXU0ZMT&Z)>-5
MPXNW=YNW1)F`<2RRLV1),@"(!F80#;CRGRUIJIU#"12...&0%GHC*YC6<>S+
MZEU"&AMME"E="NL/5O4^M;273U1ZI-1$_`3>HFTL5-0DQ>>X<E%2L:]K2(;O
M(Z28.ZA5;/&3MNL8BB2A3$.4V0ACFYWR7E.CRQB5124;`J6:1:DJ`,TJE8;Y
M3YQ'1RWCV-U&-TC-34.*;6\D$$WB8LB5"+[\`'<!C<(;MPB`?9V8CZ22H!2N
MMQD=$S!=H`2@I3<(R,98\@7OG,76NA0NK>V451-RJ^HZ)=6TI=V\BZ8K"H(&
M,=.UJXEFZSERPC'[9HLNHV(4AC&()C$#(=F#\\+V2\JYBTYQ"OQRA8J:Q%:I
M"5KXIA'`#*P@7Q%WXRL\9KR]J[A&'8!75%+3FD:4I*"`"LN&VT'9+DL@FB&$
MY6#$``Y@[`QS,8W$<1[,F/$<YQ,<YC;Q$1$1WX`>K2@/*7,I/&H6"^1L%VR)
M.Z4=G04X;3Q$M)F9_9%MIVQ]4Y\@'OLL@'8&0#_K9YXUI]KZK94D[RD_1&=1
M22$SD39>-L8CDHB@?>;8`\'=V@80``R$39!L]W%3FKA85P*0H$JV$;;YWQXX
MPVZ%,J$V2@B4Y35;MO\`(1`\^A2SFO&E-;\E4]ZHN];6S2A[M`V5JZLW<K1Y
M_"3QPK2@IQ2M22*9$Q2X>S!V?XH=FS/!>ZI9BT6J-)FJ;*9HQFU!8X@A+O:"
MP%R:E>H9FVS?9*4`-HID;73"=:7\7SH*LY2<<J".-:>`@*4&CP@@B20)66[9
MSG!#Z9A*8"CL'+WQ@':(;PP(J"ZM,U)*1P[TW\T'VMYM:I-F2@=H($ARV>>+
M@G-D;(3#EEM#(1#;T=W%-I6E7WG5.^4>MJ;4J0,S\T401$.^,8/L<.?V]^+$
M-J"N+C61N,OH$4DBZ:5'D_MCOQ%X??CEQ99[,\^YNQGV[(NDJ=T>8K2BZ<N%
M2E24-6,/'U#2580DE3E30,FB5S'S$'+M%F,E'.T#E,4Z+MHN<AND`',,AR$/
M:5UVCJFZBF/"6U<0(G/B%W1&"J88K:5=+4)XFEI(/3$5CS4-`E0\N_5W7%DG
M*3UU;&<.O6MDZH=D4ZJ>MI,O%@91ZKS@!-2:I%QQ1KX`$3=8@57<J41D%T[S
MF,XY=IJI"@NL0SV=4DRGQ`D$@76B1@1\ZY>?R_C"J>^F4OC04W`&T"W:-L*_
MO]SIKJ7MY6=GM!SQW.EN+$R)J0OA<1990I:TLS0JC$UM83MA5DUG$A-D*1&;
M`2]^G$E`PCV@P81F%:54>&9_J<PM*:]A`#K"`#-+JU#BXIB4@)E,B93V2$=7
M%,^U5;EAG#&BZFJ!X5J)$B@"Q*;>*<[;;#&Q/9\>6>;63J33U`73@0D-..FZ
M<CI=="0:YQER[NI'2?TK20I+$!)[&4R`$E9;(1*;A00.&2HACS7'/O\`2V!#
M`<*6EW$ZU)#DI%2$J$E2G=?]$=+2[*=/C%5^,5R#[,R1)*IS*MDB+Q9M,2,R
MT<W71,@L@@L@<,CMUTB+-SAM$"F14*9,2YCNX=P!EED&`L*W4@%E12X+E;1T
MP2G"D([*0+1O$HP#0$,42B,+#"(B/?!&LP$!$PB`@'4#MV[=N_&05E>GK5#T
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MP0!$>@E<P@;"!WI`#<`!T!MVX.W/;26\IXPI$^!=$HB?[,H%K*Z^/,5&K9[2
MG_:$2YW[:7]=]W$:Z.H/VU><P:2>JKG$7\9HM@3GG@G`-9%K.(Q4DRVMI45%
ME#D(D0`KJ6$3J*&XBIIE*4>(PAD4`$1Q)!X15.#2S&5);4H,U*W+)>O]V/NT
MS/7LVR%M\1->-Y+(UIP8N$(*Z)H$FY([0^N93/"+9[;#9"J=0/.2JM&M'=JM
M&]K4[I/*=018/ZW>Q%1U0T?NV""1)`U,TK3223MY%M5>),KQPL4C@2"9(O`'
M$+09*\,V&UN$',&IN+)P=E]Q19:"D)>2)DE3H=!$E`IX`@DBWBE#U9T\7>-,
M8DC`]'L&7C;C3#8>=4AQ34Y2`9[,@SGQ<9<%TN';&GZ`YV]^J#JUI`ZFK%Q@
M1)E45)%2GX.IJ`K6-C%#EZ]XPIVI5GC2H.K*;/J2F1,8Q<BGXAPK\0\'N7<?
MPMZHT_S*FHJFVE+"75LD+"1,IDTDJFJX67PBL+\;N><!Q5BCU*RTW1T3SZ4+
M6A#R5(2HR*@7"$32#,3.SH@B6UEUZ'O?;^F[DVVF4J@H^JXU)_%R:!B<904`
MH.&+UOU@JLI)D?-)=$X`=)4!`=H8!G'L&Q3+6,U."8U3.L5#*`%@[3.7JGTW
M'9$A>5\U8)FK!J7,&`O)J:!V?"4FT&7U^:<-;:2^9S5^H_5G4FFZ4M33=+Q4
M"%R#)U4PJ.4DY%QY!R_8D4S1[IBV;(@_*41/D<>`=V>_!#ZC>'JCR'I72:@.
M5BGW:H4JBT!8.W;"TVE(,T)D%6WSE9;`T:1>)G%-1=5Z[3RMH&6/9%U20Z"9
MD,.*3*7%*:I>K9SPO751JQM5I*MZI<"Z$FOUSI55C2E'Q!6[JI:QFB(=>$7"
MM53$(!4TS@9PZ4,1NW2'B.;,2E%GLB:<9EU0S$UEO+32NT<6DJ?G]VVBXJ<.
MP"<Y)!496"^'PU-U5RCI-@+F8LU5!"0A0:IP`7'7;PE,A83=-1";;3.&'WO.
M$UOW=E9=;3GIPB%*=BW9D^I9TE65SWZ#;/(A)>4AS1\8Q=&*&8D(GL'<`[\%
ML/"KIA@B?8\_YD6S7I/"H,K;X9[2.T'%+GM@%SXR=9<QU9?R5E<N8*9E)++J
ME%.R9$TD\QENC;=@^=U,,ZV1H/5S:0*$4.];,'U84JA.Q@TXLX.5$JU5T)4V
M<@P8(J'#K7#98PD)WXIF+MQQLW>$5FHR^K,VE^,?BC#22I3*R.V4!L3P)#>_
MK$<\++(7C8JSC#&`:J8,<+J:AP)#J$J2E`)EVBPM4^$;>$$\D/\`_EI2_D=Y
M>^'(KR/\$>4WE'VYMX&\G^R=N\,>$>/LW@_L7QO6<7#P;<!][!7?B'X3V*_Q
M#C[/@D>/BNZM\YV2O@[?Q;!?PK\=]L1^!]EVW;S/!V<I\4Y=6/8YAW0_1QIQ
MU)B!KO:>;>Z=*AT%M:[NG--J=O'0M?PZ6GAXQ;HNJAJ.I9XZ2-4T/V?KT%ST
MS)TXW4>OU0XBLC,D5A#/89X]"ZO&D9O]CP=2C1N>\"9X4@73O`/)9.9AL=5&
M*%67C5NR%2@@)-DY&^6T]&VS;$=VH)@`^S,P$$I-A,P4#+@`!,78(F+[X=@#
MM',,&_7*IG$*8I$D/E)"218%2G?=*!:IYJ4";@0>C;Y!\T2IW)S_`,-(\NG3
M272F&5LS46AX4[<#7RG_`.Y(*B%RCUH5N!LJM&JP7%QQAEU75=7DEP8CHSTG
M%AFRJ3C*E>WI<4!,F12#(%,[Q*[I@QLGHHF\`IVZ'A*5I!5*5\IF<KCS[(=(
MPE+KX5T65-Y?LXM7]7]L>8QC=ZG2/3$;Q[3;ZU.JO[B;+?S=4&#5\/WP`G^9
M=_PP,.L'Q8/X*/,(("]E$]`N\GYSM3?U#H+#3>(?XW:_EAZ8<?2#X97_`#'H
M$.Q\X/U7VN#\WZL_WE##89%^-L._F4>>%UF_X;K?X)]$1J7+Z].[1M^<O9S^
MO4)@^\_`_P!'XJ=GL"O-`FY3_/Z/^9'^T(ES?VTOZ[[N(TT=0?MJ\Y@UD]57
M.(R,9HL@2#GOG$FJZ@NJWFLS&`8H;S'\JJ@`H?;,;?[N))O!\L)T[K.V44T"
M<06M4MI"$V&(B_'<'O\`N[1!`"W5X0TA(W36YY#?*'^=`>FJC]..F^W$#$0C
M!K6%14O#5/<"H2-B)R\Y4TRQ3?N.WO\`:Y.A').2MD40,"29$N]*&8YA+K-G
MK$<_9]Q'$*A];E"W4*:IVB2$H2T>$D`7%5A.^R)!=`=.\'TYTXPNCI*5MK%G
MZ-#M0[PI*U+<'$`I1MDF<@+ANCY7,*TT4=J*TV7(92T2S5K2C*8G:TH.I4VI
M/#<34%.QKF52:M7A>%8&4R@T.U62$PI&*KGPY@`XV=$\_8KD74G#JW#U!5'4
M5#3#K2B>'A=6$%5M@*>+B!Y)7$QI>('2_!=1=,<3IL80$XE24K]0PZE">(K:
M:4M*9BWA4H`$=,-3<A*[DLHXO79)\Y65B/!\%<^G6:BA13CW;E\>GZD*W3R^
M)[:06:QRAWO$3/+,3")*>-G++-,Y@^>V$)2:QLM.<,O6*5323*\RG;N,"KX`
MLXONLXUIYB"E3IB'FB9D)!'"H`[!.S=9*$W\KPO%S2+AIE'+-/4-D/2(^4:F
M1OLF'#A>(DH5X;,,8%_!A_SL@?-.&U\*P4/%)B*BLJ2JHQ`DF\\+CAMZ8\_K
M1DJBUM<SEK8MM(."4]"5U&V4I\4EC&2AH.%43>7"FVJ`B5$DBNY1=GXA`3&%
M(@9Y`4`U]),.P_2/PZU.;EI*<>J*-56EQ-BN&7"A!5>`9B0WF<IQJZWXAB&M
MGBA9R#Q.'!:3$$TI0FU,PKUU2)E9(\1OO@K.UMK:#L]0E.6^MU`1]-4?3,<C
M'QD=%I=F`2HE`IWCPY0ZYX_<*`*BJRICJG4,(B(B.(Y\;QVKS;5NX_BKS[U2
M\HK)4I4[=UMPN$2PY8RWA>3L'I\O8*PANG8;"!)*1.0E,[Y],-D\W/2;2%X-
M.%67B80L>UNC9B*&JV,\W0(B]FJ39J%&I*>FERE`SUF6/$SIN93C%%5'O<@,
M("0/AIU1Q?(V?*/"14N+R_B#G9K0HDI!5<H`V3G('?,;H%[Q=:289G;3BMS!
M0,L,YGPM/:]HE`"E,`S6F83,F4R.6R&,F.J>NWG*]JBP?E`_+Y.ZBJ#H;K>V
M'[6K::LZ-N/7_DQVK/Y@WJ.@^JX,^#LJO59<'>X,ES1O*S?B89S)PC\%>P5Z
MMN/O3+[#4^'>4U'%=*R=\`\SKOF5WPK5&7.T^^8QBGH9V3]@?IZI?#=.8=IP
M-_";Y09Q.2<9`QDC-S+YK%Q$0P>RLK)OEDV["-C8YN=Z]D'RZIBI(M&;5`RB
MIS"!2D*(B.6(J$!U;R:5H$\5@WF=@'3=$RRPRTTNJ=("0DDDW2O,1?\`SG>9
M))\Q#57-3=,2BY=.]HAE:&L?$")B-)2,1>D"HKE/D"&(F>3KIZQ*JB<0`Z,:
MDW3V?&%$[-)-/D9/P!%<VH)Q"M0':C9(V@).\A(`F8%//^:1F'%C3,C_`.,P
M2AN4K;;^DVG]$?`O;RG;ZV3Y=5C]?L^VDABKG5(N-84,JP.20MY0-4]D0M-6
MLH80!QU=8JHJ"Z!0I2M@<LQ_;#9=#"-4,&Q;.%7D]:Q[.AI(2J=BEA5H'-].
MZ+:_)>)4&76L72D]J5'B`V)(L/,;9<T+:]G>YEPZ1M1A--]V)\&>GK4I/1L:
MS=R;DI(RW5X5")1=,5,4[@Y21T360&3B9+:4@*]E7-[PXX2&NNG7XYA*<R40
MG74@L$IE2!:9<UI'DVF.]I5F7\%Q%6!51`I7[2=R]@Y[`.:S8(D64U2J!L#9
MM#:&6W,0$-^_,,!4V7%NENH[Q(F/I@ED+2XCM&S,1P.X.]X<CB&7V]^,O$5!
M)-X<EY)QA6HK;*E7S`B-[]IM]:G57]Q-EOYNJ#!L>'[X`3_,N_X8&+6#XL'\
M%'F$$!>RB>@7>3\YVIOZAT%AIO$/\;M?RP],./I!\,K_`)CT"'8^<'ZK[7!^
M;]6?[RAAL,B_&V'?S*//"ZS?\-UO\$^B(U'E^Y!KLT:F$P>DU9T.',,Q_IM#
M]&>8AGL]T1P?VH"W?Z)Q-I"T)2:4F1O/JB[R2@3<IK4G':<);"_OAYQ9Z>B)
M<LV0'`1XAR.<0RS$>+ONC=D&>(T4N%M2DJ*;I[MO-!K%2Y*L]7A%U^R._'[B
MGZ`_JXKMD[T>4_1&"?V7/ETP);STSIDU=6X46R%$+.PI50'//J_+":4.4V6[
M-,!WY![N)(/""VXO2O%FQ:ZNKJ2G_+1*41'^.$(3K1A\^HJBI%*W@(6X+>8&
M"JJ+<L7U(TPZ8G(JP=4W`N6AR#FD=JK$M#-S)#TD%,0$!W#B/#$T.LXC5!Z8
M>2^X#R'B(,^F)6<%JZ;$,#HGD^LP[1LK!V&:08\I>V9CJ?L[=>;EE@:1D1;B
MMG[UR<2E*FV;TU)+**<1C%*.12B`9B&9MG<QERC3U5=F+#J!M,W%8A3@<LW4
MV1SL^53%#DK%\2J5A-*QA54JVZQA9@:#D'PCIU?V\-1II&&.B;2,(UVYR'JB
M/9JJ61FK8YLL@4.C$JGW^]+F&>)"/&P[1TN2\LX4@@US;J^(;;&OTQ&CX!Z6
MM>SWC]<M)]D3AX;GL^\?2Z/2>F/-<K;@-S3+@#GF'#J%,(]&9:F..SNAC;\2
M-GAQP)*+4FGH$G_)0KT1S?"VD+\5&,ESKBIQ*7^:['E[0+HVRYSKKRP7,V!3
M4G<F/%T\$I/CJS:SQ:>5.)S%`J;H9=N4H]PX99XZ.9>#'?"8AW"1Q.C!VDJ`
MMEV92%#H"3'%RU6+RQXUW/Q>;;+F.U"O6L`%25J2>8E8^>"^$#`<"F$HAM4R
MXM@ER$`S$.C/(![N(PZ0*-(@*L4E`2>>)@PKCFY]8**1^R;O-"4M<U3Q5,:/
MM1\M+J$29%M%63/B5RR7=RD:>)CVY2YYB=T]>D(7W3!AP-*J)^JU$P3#FTJ<
M?]M949;DJ"E>0#YH:K6_&*;#M(,?Q%]00A-$XA,[)J4.$?.1`74)&/`TG7.F
MA0$(L^HVQ4(1V)3\!GR=I=14@H4H\.0B1JJ501SR#B#NXEOJL60=6Z&G"Q[>
M,#KG")V]F:C#T#RE)\AB#^CP]\:(8EB1;5V*LR8:@&7UTTV*J(Z$J`ERPY'[
M3!S/&UJK>)Z`K154DUN3=J&;R]^9.+D$T'E'6K<J<4919G*"W6LYBXJB!A<)
MB)3EATS`.QR7.-/1+3=_,=6<QX@`,/I53;$Y<2DGFM"?G,]ULWFJ&:7\.H!A
M>'@E3R2%V3LE<-W+?L$#9\F'0`MS"=9M)4G.,#O;&6I79W(OO(ID_P!Q=4Y&
M/<X&A>M`.J3>U[,H%:F(7,Q&:;DX!P@7#VZHYX9RIEQ]33B#B%4DI0E/U9CA
MNGLOET0U.0LI''\82I]*TTC1"E;#9*\RMZ;[XDQ+O62MQ>BS-<6&KNG6$E;*
MX-%2=`S=.`W039)0#V+&.;IL4`("356)333.T$H`*"J*9BY<`9`Q@]>]1U[>
M+LJ6*Q#W:`DWG[6])W05-;1LU-$NB4!V:FN"7)LERC9$3WK7TIUMH=U/74TW
M7!55+*4#/F\E:@5$[,:MHB5/X0HBM(U8!("AI2'$ASG)WJ#Q)4@B!B;)',J9
MDHLXY49KU/,BL6CA4D@!.XCAG>+=MX@.<;PVIP''7&7&E\"%DI(-MAF+1LG+
MG!@^CD`<R]#7-IB3M3<BH4)#4AIT81E,UJ=P[(>3KFA@(5I1ER"D$YE7"KE%
M'L$F<`[U^WXS#DN3,+]5LE(RGF5=33$>P.S*)6@3O3Z1T[H(G3K-:\:P\4SZ
M95K8];FN'T<TH?Z`AQR`3!WH]`='1T[\@PV*@DCU;%3F.>'#=!6L<!'9SMWV
M7Q&\>TW*H$YJE6D463(<+%V4``.<I1R\'U"`CD(@.W!HZ`([/(Q#SS:&TOK(
M!$C,F1V[>&S=`QZN)6<T]L6UJ:[$"S?(2V&"`/90E2'T%7E$AR'`-3]3%XB&
M`Q<_(.@^D!$,P##3^(5;2\[-K:6%H%,+1TPY6D2#_3BT<*DGM)V[Y=&Z'8^<
M&82\K_7%QB4"ET^UGF([`#XE#:(CL``##99'`.<<-<20D>U(M.RV_P`\+'-B
MBG*U6IP%2RT9@;;0+(BN:(KVH+<5A2=PJ(G_`"?K.AZAC:KI.?:=B6=PE0PK
MM)[%2C4CM)RV%RR<HE.3C(8N8;0Q(EB+-#B##^'UO8O4KJ`@V"820)@&W;`=
MM5-10U2:B@2XA:#.V9F9\PY(<P_]YO-4Z=;MQLPV9^"K<?V-PW:=*-.TB7LC
M1YRGZ(5+FH&=G'.U[=T&4I`*`\DXK_WG<U3_`,W;C?\`2;<?V-Q[_P!J=._]
MS9^;Z(M_K[._^\O?^KZ8WW9[4]J'UKH%JO4+=:4NY7Y:B96]IV<J5*!8K-XE
M^=NHPB!&#C(EL5H,K(F,)CD$2\8B(Y8('2/"<NY#RO6U;"4TV'-5#BR)@A25
M`3($A^J`-UUL`OXFZC&\U:@X:AT+<Q6HHTM`R-LED)Z;;X)_TJ<U[_##21=-
MVLV@ZYC*SM&(4@TJ.$CTI267@XHID8MM/0SQS'.G:K9L!2-7[05F[QKP'[T<
M\Q1S]X=F<\5KN=-):ZC>P.K45K;?>"5H<)F9*`/%Q$D\/"DIE>8)33'Q7MZ>
MX<WI]J[AE;3XIA[+;:'V6BH.-@$)XD&7#PI`]?C,R;A9&K=>'->8:DJ%<Z?]
M-%)5GX.N,LSB:EJ&:C"H5)4$<JLAPTG2-+QSQ^_,K*.0(DX44VJ)B8I"``B;
M"KT;\-=7D?$D9YU6K:1JFHCVK"67!(+1)25NDR]5)!FG:/K"$KKKXM</U)R^
MO3K2FEJGWJY)9=4MLA2@Z.$I2!.^<IV\T.E<JW1]+Z4K"N7U>,RL;J76D8ZH
MZOB^))4*;CFC86=-TNHJG[]TQ:+G5<;1`'"YB_>X'KQ':JT.IF>%OX:HG!<,
M5V;2A<XI4DK7S&SA&R\$P4?A9T=J-+\D>T8LE0S+BB$N/)-S80B2$RE89#UM
MYW0S7RN%&H<T>X!2*DZ[@U$@<A3@.7])U2Y\(;2@4NWIP5OB&`1X:<'IGB/:
M7!1$)!M"4LRESRE;O@+/"WVBO%/BM2ZE1(?Q`I($@2IQ<YWS%IE;"F^<'HIK
M=&MH_659*-F'SIL2)/<IC3;,SF<@Y:G2I&IZX4:T;%*X7;((M4TWPE`QTC)D
M4'O3&$&U\,>K&".9;J=),YJ+%`ZVM%.HCUCVA]9!42!Q3,TF^5@!OASO%_H5
MF/\`J)O67(2%U%<%-^U-)FHH4T/5=0!,A,D`+'ZQG/9&PM/'/,M*O0$/&ZB*
M5K&"KV+CF[26J"BHAM5%/U4LU)V<\LW:$DV<C#/7G5]8N@J4Q2*B8"&$,L<C
M/'@]SW1XL:C)3E-59:<45M\:^%P!5H29!0]7?MW"%9I]XXLCKPIBBS^S6TF:
M`D)<+;'$V5)!$^$K24SYSOA$NMGF%USS`'].:;].]O:N1I"7FF;I:).B12L;
M@SC98Z44A(MHP[UM3E(QRRA7*@N3`&8`HL8"D`,/%I!H9AVB%.YJ/JA7TJ,6
MIVE=DV%#A!M_6EQ*58!8);)PQ.M^O6/^(T,:=Z7X?4?T^X^DNK*25*(,@3PB
MQ(O*;>>R<.*DY40)\NA?3F22C"WR=5*TO.YJ$`4"#6N\PA7L:R@3J9=<-.MJ
M=DG$.53H!4RN6W+`]GQ&U!UH&>RW_P#4!LT`3(S]G+@<*^<J`5=<.&4[8)@>
M%2G'A^5IX'#^.JJ4XF5;ZE+*F@W^R$J4)3ZQC3NKWTDKJ>HJ\:PWI8>D'XBC
M?.1]-_@OT3J\(+*/Y0/SSJGW7J=,$1CWO:?<[_WM_P#;"T.6IXLNKZM[Q[2W
MJ[_%WS%]YT?I?\7?`ZS"/SOWK/OUQ]YOOCL90][K/=>N.ZYA?#K)MP[MP[_]
M$V__`"W80_[TW=4>>%KM'/#(7,9\^5-^J#\W[#T]O.]XW?\`U<_(O\3])ZW#
MJ9/_`"T_FG>GW?JW;>7TPWN9/S$>X]7][?=\I1;Y='GUF?4_?4*4]`?SP^,X
MGQ_^0GX[Z9V?&EGOW-'YEUA[UZ(]RE[VOW.X]S?TP^`'^T;]/I]W"`'4'[(A
M;B_^\?/##^OOTC)'U+_U*I#TY//U\E(?._R5_B_X/%AR<K?DW_%>N>X[OIY?
M3.$1FKOA[G_[M\+3Y</F;JCT&/K^^]`+S3>*XCZP_EQ_"?HO483F;_SE'OG<
M_P"IZ]Y^;="@RM^7_N+_`-UU84IJE]'F\'F:^I4GZ0_F0]ZGYT/R2_A/P<L<
MC"OS2G[SO!W?6_N\L=/$_<'.IU?K=6\7_*^!Q`W%_P#S/^\+[WY/>;Y+X'W<
M\/0+O_T4-6YUO^$=,<__`#08K_J.+/\`DT5_\T&*_P"HXK_DT*&L?_P7J)OK
M:Q\SOR'SEM\A_+GXCX?#CH5GY0[\5>[F_N;CUOL^B&JS%\8X?\,>\([WONL.
M[]'+&Q>;?\K2_H0>(B>>SSM?.2>(?R=_$^[GA8>%OJ5OQ5>C\N[F]7??X>F$
M3XLOS.A^#>Y7^9][]7N_3R2C5_*E^NR?J^_G+CS?^?3Y,/$GT3\/X..OXBN[
M3\4]57O/=7?7^SOY)QP?#;^9#X'[T>Y=]?\`5^UN@C!3Y$^[?][O]\'^?`0-
M=V[U.N.;9?R_HB0Q'4VW'Y<T-BZ>/24F_5_;J]\Q7GW\8_\`._=_C?\`=L\/
MMG#X.IOB.YKWOW:X=SR;N24"[II_Y&J?ASK/>Z>]7GK\OZ_+.'+G7S=?Y'>O
M\X^2^34^6_<?P_@YX9M[OZ?^,BZ_^[]K=!%#W&K[ONU]?J_WOL[X$UUL>>FH
M?5L>-U_$'UCZ?KM_*WX_]TSQ()I#^5L_&VWNNI=]7D]$11:R_$ZO_'765WO>
M7_6^5\.D\JKQ)-^A3\Q;^C=]?/>#]<OHOX&&!U]ZB/B.X^^=UMNY8,'PU>Z*
D^&^K_HN\N\WHG#R/WG3\K]S]+`X?Z39W?RZ8*GR][Z/-'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
